BUPARVANOR

Indications

• Treatment of Babesiosis in cattle
• Management of other protozoal infections in veterinary medicine

Dosage

Children: Refer to specific veterinary guidelines for dosing in young animals, as pediatric doses depend on age, weight, and species.

Adults: Refer to specific veterinary guidelines for dosing in adult animals, as dosage may vary based on species and condition.

Mechanism of action

Buparvaquone acts by inhibiting the mitochondrial electron transport chain in protozoa, interfering with their oxidative phosphorylation process. This inhibition leads to a decrease in ATP production, essential for the survival and replication of the protozoa.

Pharmacodynamics

Buparvaquone demonstrates selective toxicity towards protozoa due to its specific interaction with the mitochondrial respiratory chain. The drug exhibits a concentration-dependent effect, with higher concentrations leading to more significant inhibition of protozoal growth. Its efficacy is influenced by the metabolic activity of the target organism.

Pharmacokinetics

Buparvaquone is well-absorbed following oral administration, with peak plasma concentrations typically occurring within a few hours. It has a high volume of distribution and is extensively metabolized in the liver. The primary route of elimination is via feces, with a minor portion excreted in urine. The half-life of buparvaquone is variable, depending on the species and dosage form.

Pregnancy

The safety of buparvaquone in pregnancy has not been established. Caution is advised.

Breast-feeding

It is not known whether buparvaquone is excreted in human milk. Caution is advised.

Storage

Store at room temperature, away from light and moisture. Keep out of reach of children.

Formulations

• {'name': 'buparvaquone', 'molecular_formula': 'C21H26O3'}

Dosage

Children: Refer to the BNF for Children for appropriate dosing information in paediatric cases, especially in instances of overdose.

Adults: Refer to the BNF for specific dosing information based on clinical circumstances, particularly in cases of overdose.

Mechanism of action

Ethylene glycol is metabolized by alcohol dehydrogenase to glycoaldehyde, which is subsequently converted to glycolic, glyoxylic, and oxalic acids. These metabolites contribute to anion gap metabolic acidosis and are responsible for tissue injury through the formation of insoluble calcium oxalate crystals.

Pharmacodynamics

The toxicity of ethylene glycol arises from its metabolites, particularly glycolic and oxalic acids. These compounds induce metabolic acidosis, lead to renal failure through calcium oxalate crystal deposition in the kidneys, and can cause neurological impairment. The anion gap increases due to the accumulation of these acids, leading to complications such as cardiovascular instability and potential multi-organ failure.

Pharmacokinetics

Ethylene glycol is rapidly absorbed after oral ingestion. It undergoes first-pass metabolism primarily in the liver, where it is converted into its toxic metabolites. The elimination half-life of ethylene glycol varies but is generally prolonged in cases of renal impairment. Renal excretion of metabolites contributes to the duration of toxicity, necessitating prompt medical intervention in cases of overdose.

Adverse effects

• Metabolic acidosis
• Renal failure
• CNS depression
• Hypocalcemia
• Cardiovascular collapse
• Pulmonary edema

Precautions

• Use with caution in patients with renal impairment
• Monitor for signs of metabolic acidosis
• Evaluate electrolyte levels, particularly calcium

Pregnancy

There is limited data on the safety of ethylene glycol in pregnancy. It should only be used if clearly needed.

Breast-feeding

It is unknown if ethylene glycol is excreted in human milk. Caution is advised.

Storage

Store in a tightly closed container at room temperature, away from heat and moisture.

Formulations

• Liquid

Indications

• Industrial solvent
• Chemical reaction medium
• Pharmaceutical formulation aid

Mechanism of action

N-methylpyrrolidone acts primarily as a polar aprotic solvent. It can solvate both polar and non-polar compounds, facilitating reactions and processes by enhancing the solubility of various substances. NMP does not ionize in solution, which allows it to stabilize intermediates during chemical reactions.

Pharmacodynamics

In pharmacodynamics, N-methylpyrrolidone exhibits properties that enhance the permeability of biological membranes, which can aid in the absorption of certain drugs. Its solvent characteristics support the dissolution and transportation of various pharmacological agents.

Pharmacokinetics

N-methylpyrrolidone is absorbed through the skin and mucous membranes, with a relatively low bioaccumulation potential. It is metabolized primarily in the liver, with metabolites excreted in urine. The half-life and specific metabolic pathways are not well defined, but it is known to undergo conjugation and oxidation processes.

Pregnancy

There is limited data on the use of N-methylpyrrolidone in pregnant women. It is advisable to avoid use during pregnancy unless the potential benefits justify the risks.

Breast-feeding

There is insufficient information regarding the excretion of N-methylpyrrolidone in human milk. Caution should be exercised when administering to breastfeeding women.

Storage

Store in a well-closed container at room temperature, away from light and moisture.

Indications

• Plant growth regulation
• Agricultural applications as a growth inhibitor

Dosage

Children: Not applicable.

Adults: Refer to the relevant agricultural guidelines for specific applications.

Mechanism of action

In an in vitro study, propylene acts as a plant growth inhibitor by inhibiting the oxidation of indole-3-acetic acid by peroxidase in the presence of superoxide anion radicals. This inhibition is linked to the activation of an iron complex (compound III) shuttle, which enhances the reaction rate between superoxide and peroxidase, ultimately affecting plant growth processes. Propylene is a less effective inhibitor compared to ethylene.

Pharmacodynamics

The pharmacodynamic effects of propylene are primarily observed in its role as a growth inhibitor in plants. By modulating the oxidation of phytohormones like indole-3-acetic acid, propylene can influence various growth responses in plants, potentially affecting processes such as cell elongation and division.

Pharmacokinetics

Information on the pharmacokinetics of propylene in humans is not well-documented, as its primary uses are industrial and agricultural. Its metabolism may be influenced by environmental factors, and its effects are primarily studied in the context of plant biology rather than human pharmacology.

Indications

• Used as an emulsifier in pharmaceutical formulations
• Improving the solubility of poorly soluble drugs
• Stabilizing emulsions in topical and oral medications
• Used in laboratory settings as a surfactant

Dosage

Children: Dosage varies based on formulation and intended use, refer to specific product guidelines.

Adults: Dosage varies based on formulation and intended use, refer to specific product guidelines.

Mechanism of action

Tween works by reducing the surface tension of the liquid it is mixed with, allowing for better mixing of hydrophilic and hydrophobic substances. This property makes it effective in enhancing the delivery of drugs that are poorly soluble in water. Tween can also stabilize emulsions by forming a protective layer around droplets, preventing them from coalescing.

Pharmacodynamics

As a surfactant, Tween enhances the solubility of lipophilic compounds and improves the absorption of drugs through biological membranes. Its application in drug formulation can lead to increased bioavailability and improved therapeutic effects, especially for poorly soluble drugs.

Pharmacokinetics

Tween is generally not absorbed significantly in the gastrointestinal tract when ingested. Instead, it has a local effect in the gastrointestinal tract and may influence the absorption of other compounds. The metabolism of Tween is not well characterized, and its excretion primarily occurs through feces. The overall pharmacokinetic profile is influenced by the specific formulation in which it is used.

Pregnancy

Tween (polysorbate 20) is generally considered safe for use during pregnancy. However, it should be used only when clearly needed and after consultation with a healthcare provider.

Breast-feeding

Tween is considered safe for use during breastfeeding. Its absorption and systemic exposure are minimal, but it is advisable to consult a healthcare provider.

Storage

Store at room temperature, away from moisture and heat. Keep tightly closed in a cool, dry place.

Mechanism of action

Ethylene glycol is metabolized by alcohol dehydrogenase to glycoaldehyde, which is then metabolized to glycolic, glyoxylic, and oxalic acids. These acids, along with excess lactic acid are responsible for the anion gap metabolic acidosis. Oxalic acid readily precipitates with calcium to form insoluble calcium oxalate crystals. Tissue injury is caused by widespread deposition of oxalate crystals and the toxic effects of glycolic and glyoxylic acids.

Mechanism of action

In an in vitro study of the mechanism of action of ethylene as a plant growth inhibitor, the effects of ethylene and some of its analogs, including propylene, on the oxidation of indole-3-acetic acid were examined. Ethylene and its analogs inhibited the oxidation of indole-3-acetic acid by peroxidase under conditions where the iron complex (compound III, an oxy-ferrous complex of peroxidase) shuttle was activated. Inhibition occurred only in the presence of the superoxide anion radical 02(-). Spectral and kinetic data indicated that ethylene and its analogs enhanced the rate of reaction of 02(-) with peroxidase; ie, the iron complex (compound III) shuttle, resulting in the formation of compound III. Propylene was a less effective inhibitor than ethylene.